Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring

TheMotleyFool

0 0

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring: https://g.foolcdn.com/editorial/images/777426/two-investors-put-sticky-notes-on-glass-wall.jpg

As a psychedelic therapy developer, Compass Pathways (NASDAQ: CMPS) is on the cutting edge of innovation in treating mood disorders. That makes it an exciting, if quite risky, investment.

But a lot of that risk burden could be alleviated soon, thanks to a pair of upcoming catalysts. If that happens, the stock has a high chance of skyrocketing. Let's take a moment to understand both of these two looming key events.

Compass' lead program is called COMP360, and for now it's being investigated in late-stage clinical trials for its utility in helping people with treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), and anorexia.

Source Fool.com

Like: 0

CMPS

Share